REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12, 2026 in New York. Details of the event are as follows: Date: Thursday, February 12, 2026 Time: 2:00p.m. ET The l.

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $11.11 and traded as low as $7.87. Adicet Bio shares last traded at $8.28, with a volume of 137,944 shares. Analyst Upgrades

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 642,724 shares, a decline of 95.7% from the December 15th total of 14,910,583 shares. Currently, 7.0% of the shares of the stock are

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $11.22 and traded as low as $8.07. Adicet Bio shares last traded at $8.45, with a volume of 116,371 shares traded. Wall Street Analyst Weigh In Several research

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2026. “Heading into 2026, we are proud of the strong execution across our pipeline. Since reporting data in October from our prula-cel Phase 1 program in autoimmune diseases, enrollment has more than doubled with.

Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 14,910,583 shares, a growth of 40.3% from the November 30th total of 10,629,486 shares. Based on an average daily trading volume, of 2,860,587

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet's common stock, par value $0.0001 per share. The reverse stock split ratio approved by the board of directors is within the previously disclosed range of ratios for a revers.

Shares of Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $0.72 and traded as low as $0.4859. Adicet Bio shares last traded at $0.5110, with a volume of 1,385,602 shares traded. Analyst Upgrades and Downgrades Several

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 28, 2025. One individual was hired by Adicet in November 2025 and granted new hire non-qualified stock options to purchase 20,600 shares of Adicet's common stock with an exercise price of $0.65 per share, the closing price of.

Shares of Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have assigned a buy rating and one has